Truist Securities analyst Gregory Renza reiterated a Buy rating and $210.00 price target on Revolution (NASDAQ: RVMD).

The analyst commented: "We met with mgmt today to discuss key investor topics. Our takeaways: (1) the U.S. NDA submission is nearing completion, while the EMA phased review could shorten the EU regulatory timeline, with U.S. approval expected ahead of EU approval; (2) the company remains on track to outline the 1L NSCLC strategy and broader CRC roadmap in 2H26 (with decisions typically informed by clinical data); (3) mgmt is encouraged by daraxon + PRMT5i in MTAP-deleted PDAC, with additional efficacy and safety/DDI data needed to select the optimal partner; (4) zoldon's RASolute 305/309 strategy is to preserve optionality and competitive positioning in 1L KRAS G12D PDAC."

For an analyst ratings summary and ratings history on Revolution click here. For more ratings news on Revolution click here.

Shares of Revolution closed at $191.13 yesterday.